Genmab A/S (NASDAQ:GMAB) Receives $39.17 Consensus Target Price from Analysts

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $39.17.

GMAB has been the subject of several recent research reports. Truist Financial lowered their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research note on Thursday, February 13th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st.

Institutional Investors Weigh In On Genmab A/S

A number of large investors have recently added to or reduced their stakes in the stock. Marotta Asset Management boosted its position in Genmab A/S by 5.8% during the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after purchasing an additional 739 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after buying an additional 827 shares during the last quarter. Gallacher Capital Management LLC lifted its holdings in shares of Genmab A/S by 6.8% during the first quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock worth $281,000 after buying an additional 915 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Down 1.0%

NASDAQ:GMAB traded down $0.22 on Monday, hitting $20.81. 1,247,688 shares of the company's stock traded hands, compared to its average volume of 1,129,633. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $28.96. The firm has a 50-day moving average price of $19.77 and a 200-day moving average price of $20.70. The company has a market cap of $13.34 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.